$1.03+$0.0300 (+3.00%) on the dayAs of the close; data may be delayed.
SRXH price, last 12 months
$34.98$0.8000
Daily closes over the last 260 trading sessions: −94.9%. Highest close $34.98 on , lowest $0.8000 on . Market data may be delayed.
Key stats
Previous close
$1.00
Open
$0.9950
Day range
$0.9701 – $1.21
52-week range
$0.7102 – $42.61
Volume
1.1M
Avg volume (20 days)
465.9K
Market cap
$19.3M
Performance
1W−16.0%
1M−26.6%
3M−55.8%
6M−91.1%
YTD−94.2%
1Y−93.7%
vs S&P 500, 1Y−97.8 pts
Technicals and fundamentals
About SRX Global Inc
SRX Global Inc is an AI-driven platform focused on investing in operating companies, strategic assets, and technology-enabled opportunities across multiple sectors. It uses technology and data analytics to identify and manage investments.
Chart SRXH with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full SRXH chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)16.3%average true range, % of price
52w low $0.710252w high $42.61
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)—
PEG—
Price / sales1.24
Price / book0.11
EV / EBITDA—
P/E since Jun 113.9 – 123.1
Company figures as of Nov 20, 2026.
Earnings
Next results, expectedaround Aug 18, 2027 (in 270 days)A year after its Aug 19, 2026 results release; the last came Aug 19, 2026. An estimate from its SEC filings, not a date the company announced.
Dividends & splits
Paid, last 12 months$0.05
Yield at today's price6.25%
Change vs the year before—
Jul 22$0.05
Splits
Jul 6, 20261-for-60 (reverse)
Seasonality
-40.4
J
-8.0
F
+3.0
M
-11.7
A
-37.5
M
-3.8
J
-54.0
J
+13.1
A
-15.9
S
-20.1
O
+14.0
N
-33.3
D
Average return in each calendar month, May 31, 2025 to Oct 31, 2026. 2 years is 2 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−40
−8
+3
−12
−3
−18
−75
+22
−8
−35
−93%
2025
−72
+10
−33
+4
−24
−5
+14
−33
−88%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Jun 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
SRX is acquiring CERo Therapeutics and demonstrating confidence in the engineered T-cell therapy space. The company is actively supporting clinical trial advancement with site expansion and manufacturing capabilities, positioning itself in a growing therapeutic area validated by major pharma investments.
Strategic acquisition of innovative oncology asset with clinical progress; expected to provide shareholders exposure to differentiated immunotherapy platform and accelerate value creation through enhanced operational resources and capital access.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.